Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2

• Published in: Molecular cancer therapeutics Vol. 19; no. 10; pp. 2023 - 2033
• Main Authors: Li, Qiaqia, Liu, Kilia Y, Liu, Qipeng, Wang, Guangyu, Jiang, Weihua, Meng, Qingshu, Yi, Yang, Yang, Yongyong, Wang, Rui, Zhu, Sen, Li, Chao, Wu, Longxiang, Zhao, Dongyu, Yan, Lin, Zhang, Lili, Kim, Jung-Sun, Zu, Xiongbing, Kozielski, Anthony J, Qian, Wei, Chang, Jenny C, Patnaik, Akash, Chen, Kaifu, Cao, Qi
• Format: Journal Article
• Language: English
• Published: United States 01-10-2020
• Subjects: Butyrophenones - pharmacology; Butyrophenones - therapeutic use; Enhancer of Zeste Homolog 2 Protein - drug effects; Female; Histamine H1 Antagonists - pharmacology; Histamine H1 Antagonists - therapeutic use; Humans; Male; Piperidines - pharmacology; Piperidines - therapeutic use
• ISSN: 1535-7163; 1538-8514; 1538-8514
• DOI: 10.1158/1535-7163.mct-20-0250

Enhancer of zester homolog 2 (EZH2), a histone lysine methyltransferase and the catalytic component of polycomb repressive complex 2, has been extensively investigated as a chromatin regulator and a transcriptional suppressor by methylating H3 at lysine 27 (H3K27). EZH2 is upregulated or mutated in most cancers, and its expression levels are negatively associated with clinical outcomes. However, the current developed small-molecule inhibitors targeting EZH2 enzymatic activities could not inhibit the growth and progression of solid tumors. Here, we discovered an antihistamine drug, ebastine, as a novel EZH2 inhibitor by targeting EZH2 transcription and subsequently downregulating EZH2 protein level and H3K27 trimethylation in multiple cancer cell lines at concentrations below 10 μmol/L. The inhibition of EZH2 by ebastine further impaired the progression, migration, and invasiveness of these cancer cells. Overexpression of
wild-type and its mutant,
(lacking methyltransferase activity), rescued the neoplastic properties of these cancer cells after ebastine treatment, suggesting that EZH2 targeted by ebastine is independent of its enzymatic function. Next-generation RNA-sequencing analysis also revealed that C4-2 cells treated with 8 μmol/L ebastine showed a gene profiling pattern similar to
-knockdown C4-2 cells, which was distinctively different from cells treated with GSK126, an EZH2 enzyme inhibitor. In addition, ebastine treatment effectively reduced tumor growth and progression, and enhanced progression-free survival in triple-negative breast cancer and drug-resistant castration-resistant prostate cancer patient-derived xenograft mice. Our data demonstrated that ebastine is a novel, safe, and potent anticancer agent for patients with advanced cancer by targeting the oncoprotein EZH2.